Acutus Medical Analyst Ratings
Acutus Medical Analyst Ratings
While ratings are subjective and will change, the latest Acutus Medical (AFIB) rating was a maintained with a price target of $1.00 to $1.50. The current price Acutus Medical (AFIB) is trading at is $1.45, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2022 | 3.45% | Goldman Sachs | $1 → $1.5 | Maintains | Neutral |
| 06/24/2022 | 3.45% | BTIG | $2 → $1.5 | Maintains | Buy |
| 04/27/2022 | 37.93% | BTIG | → $2 | Upgrades | Neutral → Buy |
| 04/14/2022 | -31.03% | Goldman Sachs | $5 → $1 | Maintains | Neutral |
| 01/20/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 01/14/2022 | 106.9% | Canaccord Genuity | $10 → $3 | Downgrades | Buy → Hold |
| 11/12/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/12/2021 | 589.66% | Canaccord Genuity | $18 → $10 | Maintains | Buy |
| 10/22/2021 | 589.66% | Goldman Sachs | → $10 | Initiates Coverage On | → Neutral |
| 07/15/2021 | 1141.38% | Canaccord Genuity | $11 → $18 | Upgrades | Hold → Buy |
| 03/19/2021 | 1003.45% | Canaccord Genuity | $30 → $16 | Maintains | Hold |
| 03/19/2021 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 03/19/2021 | 1210.34% | JP Morgan | → $19 | Downgrades | Overweight → Neutral |
| 01/14/2021 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 08/31/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 08/31/2020 | 1968.97% | Canaccord Genuity | → $30 | Initiates Coverage On | → Hold |
| 08/31/2020 | 2520.69% | B of A Securities | → $38 | Initiates Coverage On | → Buy |
| 08/31/2020 | 2589.66% | JP Morgan | → $39 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/16/2022 | 3.45% | 高盛 | $1 → 1.5 美元 | 維護 | 中立 |
| 2022 年 6 月 24 日 | 3.45% | BTIG | $2 → 1.5 美元 | 維護 | 購買 |
| 04/27/2022 | 37.93% | BTIG | → 2 美元 | 升級 | 中性 → 買入 |
| 2022 年 4 月 14 日 | -31.03% | 高盛 | 5 美元 → 1 美元 | 維護 | 中立 |
| 01/20/2022 | — | BTIG | 降級 | 買入 → 中性 | |
| 2022 年 1 月 14 日 | 106.9% | Canaccord Genu | 10 美元 → 3 美元 | 降級 | 買入 → 持有 |
| 11/12/2021 | — | 摩根大通 | 降級 | 中性 → 體重不足 | |
| 11/12/2021 | 589.66% | Canaccord Genu | 18 美元 → 10 美元 | 維護 | 購買 |
| 2021 年 10 月 22 日 | 589.66% | 高盛 | → 10 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 2021 年 7 月 15 日 | 1141.38% | Canaccord Genu | 11 美元 → 18 美元 | 升級 | 持有 → 買入 |
| 03/19/2021 | 1003.45% | Canaccord Genu | 30 美元 → 16 美元 | 維護 | 保持 |
| 03/19/2021 | — | 威廉布萊爾 | 降級 | 跑贏大盤 → 市場表現 | |
| 03/19/2021 | 1210.34% | 摩根大通 | → 19 美元 | 降級 | 超重 → 中性 |
| 2021 年 1 月 14 日 | — | B of A 類證券 | 降級 | 買入 → 中性 | |
| 08/31/2020 | — | 威廉布萊爾 | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 08/31/2020 | 1968.97% | Canaccord Genu | → 30 美元 | 啓動覆蓋範圍開啓 | → 按住 |
| 08/31/2020 | 2520.69% | B of A 類證券 | → 38 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/31/2020 | 2589.66% | 摩根大通 | → 39 美元 | 啓動覆蓋範圍開啓 | → 超重 |
Acutus Medical Questions & Answers
Acutus 醫學問題與解答
The latest price target for Acutus Medical (NASDAQ: AFIB) was reported by Goldman Sachs on August 16, 2022. The analyst firm set a price target for $1.50 expecting AFIB to rise to within 12 months (a possible 3.45% upside). 9 analyst firms have reported ratings in the last year.
高盛於2022年8月16日公佈了Acutus Medical（納斯達克股票代碼：AFIB）的最新目標股價。該分析公司將目標股價設定爲1.50美元，預計AFIB將在12個月內上漲至1.50美元（可能上漲3.45％）。去年有9家分析公司公佈了評級。
The latest analyst rating for Acutus Medical (NASDAQ: AFIB) was provided by Goldman Sachs, and Acutus Medical maintained their neutral rating.
Acutus Medical（納斯達克股票代碼：AFIB）的最新分析師評級由高盛提供，Acutus Medical維持中性評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acutus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acutus Medical was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Acutus Medical的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Acutus Medical的最後一次評級是在2022年8月16日提交的，因此您應該預計下一個評級將在2023年8月16日左右公佈。
While ratings are subjective and will change, the latest Acutus Medical (AFIB) rating was a maintained with a price target of $1.00 to $1.50. The current price Acutus Medical (AFIB) is trading at is $1.45, which is within the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的Acutus Medical（AFIB）評級維持不變，目標股價爲1.00美元至1.50美元。Acutus Medical（AFIB）目前的交易價格爲1.45美元，在分析師的預測區間內。
